• Fresenius Kabi secured exclusive U.S. commercialization rights for an FDA-cleared rituximab biosimilar referencing Rituxan.
• Dr. Reddy’s Laboratories developed, manufactured, and filed the biosimilar, positioning Fresenius Kabi to expand its U.S. biosimilars portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.